Benzinga · Oct 7, 2026
Barclays Maintains Overweight on Repligen, Raises Price Target to $225
Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $175 to $225.
RG
NASDAQ · RGEN
Repligen Corporation
Healthcare · Medical - Instruments & Supplies
$178.20
Up+$2.78 (+1.58%)
Updated Oct 15, 2026, 10:18 AM
SID Score
5.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 9.1B
- P/E ratio
- 5,229.48
- Dividend yield
- 0.00%
- 52-week range
- $100.99 – $198.87
- Volume
- 1.22M
- Avg. volume
- 934.31K
Price performance · RGEN
RGEN price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 14, 2026
RGEN closed at $178.20 after 21 trading sessions, up 3.06% for the selected period.
- Last close
- $178.20
- Period change
- +3.06%
- Period low
- $163.84
- Period high
- $194.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 14, 2026 | $175.42 | $181.0667 | $175.39 | $178.20 | 1.22M |
| Oct 13, 2026 | $172.51 | $177.955 | $169.73 | $175.42 | 1.26M |
| Oct 12, 2026 | $171.73 | $173.82 | $169.90 | $172.51 | 899.61K |
| Oct 9, 2026 | $164.21 | $174.82 | $164.21 | $173.88 | 1.34M |
| Oct 8, 2026 | $164.00 | $164.65 | $157.4355 | $163.84 | 1.23M |
| Oct 7, 2026 | $174.75 | $175.04 | $165.99 | $167.22 | 2.63M |
| Oct 6, 2026 | $191.90 | $194.36 | $174.36 | $174.86 | 1.7M |
| Oct 5, 2026 | $178.75 | $191.26 | $178.61 | $189.50 | 1.61M |
| Oct 2, 2026 | $179.32 | $186.52 | $178.00 | $181.70 | 1.46M |
| Oct 1, 2026 | $194.00 | $194.00 | $177.12 | $177.23 | 1.95M |
| Sep 30, 2026 | $193.09 | $195.61 | $190.965 | $192.23 | 730.44K |
| Sep 29, 2026 | $196.00 | $196.65 | $190.98 | $194.57 | 1.14M |
| Sep 28, 2026 | $187.25 | $198.87 | $187.11 | $194.09 | 1.57M |
| Sep 25, 2026 | $189.92 | $191.51 | $186.905 | $189.68 | 1.5M |
| Sep 24, 2026 | $184.10 | $192.49 | $183.75 | $190.65 | 1.6M |
| Sep 23, 2026 | $186.38 | $188.945 | $181.71 | $184.53 | 934.77K |
| Sep 22, 2026 | $180.72 | $188.20 | $180.00 | $186.75 | 1.16M |
| Sep 21, 2026 | $176.89 | $182.2499 | $176.22 | $180.71 | 857.65K |
| Sep 18, 2026 | $179.10 | $179.10 | $176.29 | $176.89 | 1.36M |
| Sep 17, 2026 | $174.93 | $178.65 | $173.24 | $178.19 | 1.09M |
| Sep 16, 2026 | $174.90 | $178.55 | $171.66 | $172.91 | 826.9K |
Latest RGEN news
The latest Smart Investors Daily articles mentioning RGEN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RGEN research
Overview
Company profile and research snapshot.
Company profile
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $171.00
- Implied upside
- —
- Analysts
- 28
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Overweight | — |
| Sep 9, 2026 | UBS | Buy | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
| Jul 29, 2026 | JP Morgan | Overweight | — |
| Jul 7, 2026 | Benchmark | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 29, 2026
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.
Yahoo · Sep 23, 2026
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
Yahoo · Sep 22, 2026
JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study
J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
